2092 Background: The use of radiotherapy plus TMZ administered concomitantly with and after radiotherapy (Stupp platform; SP) for HGG was shown to improve median and 5-year survival. To compare these results with routine clinical practice a bidirectional registry was established by RedLANO. Methods: A total of 171 HGG patients treated with SP were included. Time to progression (TTP) and overall survival (OS) were estimated. Results: The median age was 56-yo (17-84 years) and 97 patients were male (56%). 82% had GB of which 62% were primary tumors; 55% of cases were treated with debulking surgery and 23% had undergone biopsy. 77% of patients completed the SP, with a median radiation dose of 58.2 Gy (r,18-64) and a mean number of TMZ cycles of 5 (SD + / -3). Pseudoprogression was documented in 20%, the median OS was 15.8-mo (IC95% 11.9-19.7 mo) and the TTP was 9.5-mo (IC95% 8.3-12.7 mo). The 1-y and 2-y survival rates were 69% and 31% respectively. In the retrospective analysis, the patients with a post-operative KPS over 70% showed more prolonged survival (p=0.05), as well as those with better RPA classification (p=0.04) and without multicentricity (p=0.049). Seventy-one patients (41%) were treated with second line therapy (Bev combos 32; metronomic or dose dense TMZ 24; BCNU 14; other 2) after the tumor had recurred. Conclusions: This study is the largest study of radiotherapy plus concomitant and adjuvant TMZ for HGG in Latin American patients. The median and 2-y survival outcomes in this study are comparable to previous reports.